Despite CureVac N.V.’s (CVAC) own lack of news, several stocks in the sector have been impacted due to a piece of larger market news, As the CureVac N.V, (CVAC) stock plunged -11.33% to $103.05 in the premarketing session today.
However, the company announced on December 14, 2020, that a pivotal Phase 2b/3 study of its mRNA vaccine candidate, CVnCoV, has enrolled its first participant against COVID-19. CVAC is developing transformative medicines based on messenger ribonucleic acid (mRNA).
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Researchers at the randomized, observing blind, placebo-controlled Phase 2b/3 trial HERALD are planning to assess the safety and efficacy of CVnCoV at a dose of 12 g across Europe and Latin America.
There are also two primary efficacy objectives in addition to the primary safety objective: demonstrating the efficacy of CVnCoV in preventing COVID-19 cases of any severity in participants who have never been infected with the SARS-CoV-2.
There are also two primary efficacy objectives in addition to the primary safety objective: demonstrating the efficacy of CVnCoV in preventing COVID-19 cases of any severity in participants who have never been infected with the SARS-CoV-2.
Researchers will assess the effect of CVnCoV by analyzing symptomatic COVID-19 disease in a certain number of participants based on an event-driven analysis. As part of the participants’ continuous safety monitoring in the trials, the data will be reviewed regularly by an independent Data Safety Monitoring Board.
The extension study will collect additional data to assess and evaluate the durability of vaccine efficacy, the persistence of antibodies to SARS-CoV-2, and the occurrence of COVID-19 cases after completion of the trial.
